{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:40:03Z","timestamp":1756370403628,"version":"3.44.0"},"reference-count":11,"publisher":"SMC Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"Gemfibrozil is a lipid-regulating agent used mainly to treat patients with hypertriglyceridaemia, especially those at risk for acute pancreatitis. Like any other pharmacological agent, gemfibrozil has known adverse effects, mainly gastrointestinal, such as cholelithiasis, gallstones, elevated transaminase, and other non-specific symptoms including dyspepsia, nausea and vomiting. Other reported adverse reactions are dizziness and vertigo, myopathy and rhabdomyolysis, angioedema, urticaria and rash. As far as we knew, gemfibrozil does not have urinary tract adverse reactions. In this report, we present a case of polyuria secondary to gemfibrozil with a score of 9 on the Naranjo scale, and a literature review.<\/jats:p>","DOI":"10.12890\/2021_002546","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T10:11:37Z","timestamp":1621937497000},"source":"Crossref","is-referenced-by-count":2,"title":["Gemfibrozil-Induced Polyuria"],"prefix":"10.12890","volume":"8","author":[{"given":"Ashraf","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Department of Medicine, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmond","family":"Okotcha","sequence":"additional","affiliation":[{"name":"Patient First Medical Center affiliated with Beaumont Hospital, Dearborn, Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul-Hussein","family":"Saad","sequence":"additional","affiliation":[{"name":"Patient First Medical Center affiliated with Beaumont Hospital, Dearborn, Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10397","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"key":"10.12890\/2021_002546_ref1","doi-asserted-by":"crossref","unstructured":"
  • Hendrani AD, Adesiyun T, Quispe R, Jones SR, Stone NJ, Blumenthal RS, et al Dyslipidemia management in primary prevention of cardiovascular disease: current guidelines and strategies. World J Cardiol<\/em> 2016;8<\/strong>(2):201\u2013210. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4766270\/pdf\/WJC-8-201.pdf<\/li>","DOI":"10.4330\/wjc.v8.i2.201"},{"key":"10.12890\/2021_002546_ref2","doi-asserted-by":"crossref","unstructured":"
  • Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care<\/em> 2013;36<\/strong>(Suppl 2):S325\u2013S330. https:\/\/care.diabetesjournals.org\/content\/diacare\/36\/Supplement_2\/S325.full.pdf<\/li>","DOI":"10.2337\/dcS13-2038"},{"key":"10.12890\/2021_002546_ref3","doi-asserted-by":"crossref","unstructured":"
  • Ito MK. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Atherosclerosis<\/em> 2015;242<\/strong>(2):647\u2013656.<\/li>","DOI":"10.1016\/j.atherosclerosis.2015.06.012"},{"key":"10.12890\/2021_002546_ref4","doi-asserted-by":"crossref","unstructured":"
  • Bussi\u00e8re-C\u00f4t\u00e9 S, Omlin T, de C\u00e0ssia Pinheiro E, Weber J-M. Gemfibrozil disrupts the metabolism of circulating lipids in bobwhite quails. Comp Biochem Physiol Toxicol Pharmacol<\/em> 2016;179<\/strong>:137\u2013143. doi:10.1016\/j.cbpc.2015.09.011<\/li>","DOI":"10.1016\/j.cbpc.2015.09.011"},{"key":"10.12890\/2021_002546_ref5","doi-asserted-by":"crossref","unstructured":"
  • Ghosh A, Rangasamy SB, Modi KK, Pahan K. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem<\/em> 2017;141<\/strong>(3):423\u2013435. doi:10.1111\/jnc.13987<\/li>","DOI":"10.1111\/jnc.13987"},{"key":"10.12890\/2021_002546_ref6","doi-asserted-by":"crossref","unstructured":"
  • Ito MK. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Atherosclerosis<\/em> 2015;242<\/strong>(2):647\u2013656. doi:10.1016\/j.atherosclerosis.2015.06.012<\/li>","DOI":"10.1016\/j.atherosclerosis.2015.06.012"},{"key":"10.12890\/2021_002546_ref7","unstructured":"
  • Quintanilla Rodriguez BS, Correa R. Gemfibrozil. Treasure Island (FL): StatPearls Publishing; 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK545266\/?report=printable<\/li>"},{"key":"10.12890\/2021_002546_ref8","doi-asserted-by":"crossref","unstructured":"
  • Haybar H, Goudarzi M, Mehrzadi S, Aminzadeh A, Khodayar MJ, Kalantar M, et al. Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats. Biomed Pharmacother Biomedecine Pharmacother<\/em> 2019;109<\/strong>:530\u2013535. doi:10.1016\/j.biopha.2018.10.101<\/li>","DOI":"10.1016\/j.biopha.2018.10.101"},{"key":"10.12890\/2021_002546_ref9","doi-asserted-by":"crossref","unstructured":"
  • Chandra S, Pahan K. Gemfibrozil, a lipid-lowering drug, lowers amyloid plaque pathology and enhances memory in a mouse model of Alzheimer\u2019s disease via peroxisome proliferator-activated receptor ?. J Alzheimers Dis Rep<\/em> 2019;3<\/strong>(1):149\u2013168. doi:10.3233\/ADR-190104<\/li>","DOI":"10.3233\/ADR-190104"},{"key":"10.12890\/2021_002546_ref10","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Navarro JA. Acute renal failure secondary to interstitial acute nephritis and Fanconi syndrome due to metamizole and gemfibrozil. Nefrologia<\/em> 2016;36<\/strong>(3):321\u2013323.<\/li>","DOI":"10.1016\/j.nefroe.2015.06.012"},{"key":"10.12890\/2021_002546_ref11","unstructured":"Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. In: LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed 24 March 2021. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/<\/li>"}],"container-title":["European Journal of Case Reports in Internal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/2546\/2660","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/2546\/2661","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/2546\/2661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:26:39Z","timestamp":1756369599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/view\/2546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.12890\/2021_002546","relation":{"has-manifestation":[{"id-type":"other","id":"1-70-2546-g2660","asserted-by":"subject"},{"id-type":"other","id":"1-70-2546-g2661","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"1-70","asserted-by":"subject"}]},"ISSN":["2284-2594"],"issn-type":[{"type":"electronic","value":"2284-2594"}],"subject":[],"published":{"date-parts":[[2021,4,27]]},"article-number":"6"}}